Spyre Therapeutics
SYRE
28 hedge funds and large institutions have $38M invested in Spyre Therapeutics in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
43% more capital invested
Capital invested by funds: $26.6M → $38M (+$11.3M)
22% more funds holding
Funds holding: 23 → 28 (+5)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
+$2.92M |
| 2 |
Jennison Associates
New York
|
+$205K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$107K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$81.4K |
| 5 |
SCM
Sio Capital Management
New York
|
+$69.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.03M |
| 2 |
Millennium Management
New York
|
-$149K |
| 3 |
Goldman Sachs
New York
|
-$129K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$62K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$37.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $5K | -$417 | -3 | -10% |
|
|
BIM
27
BlackRock Investment Management
Wilmington,
Delaware
| $5K | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $3K | -$2.23K | -16 | -47% |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$62K | -514 | Closed |
|
30
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$4K | -37 | Closed |
|
SYRE Hedge Fund Activity: Q3 2016 in Review
28 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q3 2016, worth a combined $38M — up 43% from $26.6M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SYRE positions and 2 closed out — a net gain of 5 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was University of Texas/Texas AM Investment Management Co (UTIMCO), opening a new position worth an estimated $2.92M. The largest seller was RA Capital Management, cutting an estimated $1.03M.
- 28 institutional investors held Spyre Therapeutics (SYRE) as of Q3 2016, up from 23 in Q2 2016.
- Funds reported $38M of Spyre Therapeutics stock for Q3 2016, up 43% quarter-over-quarter.
- 7 funds opened new Spyre Therapeutics positions in Q3 2016 and 2 closed out, a net change of +5 holders.
- The largest Spyre Therapeutics buyer in Q3 2016 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $2.92M added.
- The largest Spyre Therapeutics seller in Q3 2016 was RA Capital Management, an estimated $1.03M sold.
Based on aggregated 13F filings for Q3 2016.